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Abstract Objective Heart failure patients are regularly
admitted to hospital and frequently use multiple medica-
tion. Besides intentional changes in pharmacotherapy,
unintentional changes may occur during hospitalisation.
The aim of this study was to investigate the effect of a
clinical pharmacist discharge service on medication dis-
crepancies and prescription errors in patients with heart
failure. Setting A general teaching hospital in Tilburg, the
Netherlands. Method An open randomized intervention
study was performed comparing an intervention group,
with a control group receiving regular care by doctors and
nurses. The clinical pharmacist discharge service consisted
of review of discharge medication, communicating pre-
scribing errors with the cardiologist, giving patients
information, preparation of a written overview of the dis-
charge medication and communication to both the com-
munity pharmacist and the general practitioner about this
medication. Within 6 weeks after discharge all patients
were routinely scheduled to visit the outpatient clinic and
medication discrepancies were measured. Main outcome
measure The primary endpoint was the frequency of pre-
scription errors in the discharge medication and medication
discrepancies after discharge combined. Results Forty-four
patients were included in the control group and 41 in the
intervention group. Sixty-eight percent of patients in the
control group had at least one discrepancy or prescription
error against 39% in the intervention group (RR 0.57 (95%
CI 0.37–0.88)). The percentage of medications with a
discrepancy or prescription error in the control group was
14.6% and in the intervention group it was 6.1% (RR 0.42
(95% CI 0.27–0.66)). Conclusion This clinical pharmacist
discharge service significantly reduces the risk of discrep-
ancies and prescription errors in medication of patients
with heart failure in the 1st month after discharge.
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Impact of findings on practice
• The studied clinical pharmacist discharge service
reduces the percentage of heart failure patients with one
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or more discrepancies or prescription errors by almost a
half (68% vs. 39%).
• The information about medication at discharge for heart
failure patients needs to be optimized for community
pharmacists, for general practitioners, and for the
patients.
Introduction
Heart failure is a chronic, progressive disease characterized
by frequent hospital admissions and high mortality rates
[1]. The primary goals of improving disease management
in patients with heart failure are optimization of the
pharmacological therapy and improving adherence to
medication and lifestyle. Medication such as angiotensin-
converting enzyme inhibitors and b-blockers are well
established in the treatment of heart failure, reducing
mortality and readmissions [2]. Despite pharmacotherapy,
outcomes for patients remain poor and frequent hospitali-
sations remain necessary [3]. Hospital admissions usually
lead to changes in medication use. Most changes are
intended, for example adjusting dosage during hospital
admission. Other changes, however, are unintended as is
the case with prescription errors. In addition, medication
discrepancies after hospital discharge can occur by insuf-
ficient patient education or insufficient communication to
the general practitioner (GP) or the patient his community
pharmacist about the intentional changes [4]. A possible
consequence of these discrepancies and prescription errors
can be readmission [3].
A recent review demonstrated that pharmacist care in
the treatment of heart failure greatly reduces the risk of all-
cause and heart failure hospitalization, particularly if the
pharmacist was a member of a multidisciplinary team [5].
Yu et al. have systematically compared the disease man-
agement programmes for older patients with heart failure.
This review showed that a program must be multifaceted
and should consist of an in-hospital phase of care, intensive
patient education, exercise and psychosocial counselling,
self care supportive strategy, optimization of medical reg-
imen, and ongoing surveillance and management of clini-
cal deterioration [6]. There is also evidence that a
pharmacist intervention for outpatients with heart failure
can improve adherence to cardiovascular medications and
decrease health care cost [7]. However, the study of
Holland et al. [8] did not find a reduction in hospital admis-
sions when a community pharmacist led the intervention in
contrast to the results found when a specialist nurse led the
intervention. These studies all looked at readmission and
hospitalization. None of the studies have focused on the
reduction of medication discrepancies after hospital dis-
charge, which may be an indicator of readmission.
Several studies have been published which describe
methods to optimize medication use after hospital dis-
charge, but the most effective method has not been estab-
lished yet [9–11]. A possible useful strategy is providing
patients with more information about the (side)effects of
their medication and explaining the changes made in
pharmacotherapy during their admission. Al-Rashed et al.
[10] showed that pharmaceutical counselling before dis-
charge, together with a medication and information dis-
charge summary and a medicine reminder chart lead to
better drug knowledge and compliance and a reduction of
readmissions. Providing the patient with a copy of the
drugs prescribed on discharge, i.e. a full overview of
the current medication which can be incorporated into the
patient his medication record at the community pharmacy,
also seems to be effective. Discharging 19 patients with
such information to take to their community pharmacist
could result in the prevention of one unintentional dis-
crepancy having a definite adverse effect [11].
Research on the prevention of medication discrepancies
has mainly taken place in the USA and UK. Within these
countries the availability of hospital pharmacists is higher
than within the countries of the European continent. This
makes extrapolation of the results to the European situa-
tion difficult and projects can not be easily implemented
in European hospitals because of this manpower problem.
Several solutions are possible for the manpower problem.
First of all, the use of alternative personnel may be an
option as was shown in two Dutch studies on medication
reconciliation [12, 13]. A second solution may be to focus
the attention of the clinical pharmacist on high risk
patients during these interventions. Heart failure patients
are such high risk patients because they use a large
number of medicines and are frequently admitted to
hospital [1].
Aim of the study
The aim of this study was to investigate the effects of a
multifaceted clinical pharmacist discharge service on the
number of medication discrepancies after discharge in
heart failure patients. A secondary aim was to make an
estimation of the effect of the service on non-adherence.
Method
Design
An open randomized intervention study was performed
comparing an intervention group provided with the clinical
760 Pharm World Sci (2010) 32:759–766
123
pharmacist discharge service, with a control group pro-
vided with regular care by doctors and nurses.
The study protocol was approved by a medical ethics
committee (Medische-Ethische Toetsing Onderzoek Pati-
e¨nten en Proefpersonen, Tilburg, The Netherlands).
Setting and study population
The study was conducted at the department of cardiology
of a teaching hospital in Tilburg, the Netherlands between
May 2007 and July 2008.
Eligible patients were adults (aged over 18 years)
admitted with a diagnosis of heart failure and prescribed
five or more medicines (from any class) at discharge. We
excluded patients living in a nursing home or unable to
give informed consent, due to mental incapacity or termi-
nal illness.
All patients who provided written informed consent
were randomised using a random number table, to receive
intervention or regular care.
Regular care
Patients in the control group received regular care, con-
sisting of verbal and written information about their drug
therapy from a nurse at hospital discharge. The discharge
prescription was made by the physician and given to the
patient to hand over to the GP.
Intervention
First of all, the intervention consisted of a clinical phar-
macist identifying potential prescription errors in the dis-
charge medication and discussing them with the
cardiologist. This resulted in the final discharge medica-
tion. Furthermore, patients in the intervention group
received verbal and written information about (side)effects
of, and changes in, their in hospital drug therapy from a
clinical pharmacist upon hospital discharge. In addition to
this, the clinical pharmacist made a discharge medication
list which contained additional information related to dose
adjustments and discontinued medication. After it had been
approved by the physician, the discharge medication list
was faxed to the community pharmacy and given as written
information to the patient with the instruction to hand it
over to the GP.
All patients (both regular care and intervention) col-
lected medication at their community pharmacy and
received usual routine management by their cardiologist
after discharge. This included an outpatient visit within
6 weeks after hospital discharge and an additional visit to
the heart failure nurse if necessary.
Data collection
The following patient characteristics have been collected:
age, sex, education (primary school or higher education),
living situation (single or cohabitating), chronic co-mor-
bidity (Chronic Disease Score, CDS [14]), routine check
ups at the heart failure unit before admission, length of
admission, number of medicines at discharge, living con-
ditions after discharge (i.e. living in a nursing home, in a
residential home for elderly people or at home with addi-
tional care), patient or pharmacy control over medication
(i.e. patient is in control or the patient receives a ‘‘week
box’’, prefilled by the pharmacy; a week box contains all
the medication for a week arranged by day and hour of
intake) and New York Heart Association (NYHA) class
upon discharge.
In addition, medication was classified by ATC code and
the ‘‘source’’ of each drug, i.e. start or discontinuation
during admission, dose adjustment or preadmission medi-
cation, was noted.
During the first follow up consultation after discharge
with the cardiologist or heart failure nurse at the clinic, an
estimate of adherence was made with the ‘‘Brief Medica-
tion Questionnaire—Regimen Screen’’ (BMQ), a validated
tool for screening for adherence consisting of seven ques-
tions. This tool requires patients to list all medication taken
in the past week and subsequently for each medicine listed
four questions about the use of the medicine are asked, as
well as three general questions about medication use. For
each item patients received a score of ‘‘1’’ if their initial or
spontaneous report indicated potential non-adherence with
the current regimen for the target medication (i.e. when the
specific question was answered with ‘yes’) and a score of
‘‘0’’ if this reports indicated no non-adherence (i.e. when
the question was answered with ‘no’). The maximum score
is 7 and a score of 1 or higher is an indication for potential
non-adherence. Table 1 shows the questions of the BMQ
[15].
In addition, the patient’s medication was checked for
discrepancies and for prescription errors. Discrepancies
were discussed with the patient and the cardiologist or
heart failure nurse. A discrepancy was defined as a devia-
tion in medication use compared to the medication on the
discharge prescription. Discrepancies were classified as:
re-start of discontinued medication, discontinuation of
prescribed discharge medication, use of higher or lower
dose, more or less frequent use than prescribed and
incorrect time of taking medication.
A prescription error was defined as an error which
occurs in the process of prescribing medication, namely
dosing errors, dosage form errors, contra-indications, drug–
drug interactions and double-medication. All prescription
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errors identified by the clinical pharmacist and agreed upon
by the cardiologist were collected.
The clinical relevance of the discrepancy or prescription
error was assessed by making use of the NCC MERP-index
[16]. This index categorizes medication errors (class A-I),
using an algorithm, see Table 2 (briefly, class A: no error,
class B, C and D: error, but no harm, class E, F, G and
H: error and harm, class I: error and death). Discrepancies
and prescription errors in class E or higher (i.e. errors
resulting in harm) are considered as clinically relevant.
Three pharmacists and a cardiologist assessed the clinical
relevance; for those discrepancies they disagreed on they
met to reach consensus.
End points
The primary end point in this study is the total sum of the
percentage of prescription errors and discrepancies after
hospital discharge. The estimate of adherence as indicated
by the BMQ was chosen as a secondary end point. Patients
with a score of C1 were considered to be potentially
nonadherent [15].
Data analysis
The program PS sample size (version 2.1.31) was used to
determine the sample size [17]. The sample size was
calculated at 62 patients per group based on a = 0.05, a
power of 0.8, an estimated frequency of the end point in the
control group of 30% [3, 4, 11, 18, 19] and an expected
reduction to 10% [10, 20].
All data were processed in Microsoft Access 2003 and
analysed with SPSS version 16.0.
The average and standard deviation were determined for
continuous variables and the percentage was calculated for
categorical variables. The differences between the inter-
vention and the control group were analysed by the two
sample t test for continuous variables and by the Chi-
square test for categorical variables. A P value of B0.05
was considered to be significant.
For analysis of the primary and secondary end point the
relative risk (RR) was calculated with a confidence interval
(CI) of 95%. For the primary endpoint this was performed
both on the medication level (number of medications as
denominator) and on the patient level (% of patients with
one or more discrepancy or prescription errors), and for the
secondary endpoint on the patient level.
Results
We approached a total of 119 patients to participate after
screening them for eligibility. The 85 patients who agreed
were randomised; 44 patients in the control group and 41
Table 1 Questions of the
BMQ-Regimen Screen [15]
a Score of C1 indicates
potential non-adherence
Question Scorea
Did patient fail to list the prescribed drugs in the initial (spontaneous) report? Yes = 1; no = 0
Did patient stop or interrupt therapy due to late refill or other reason? Yes = 1; no = 0
Did patient report any missed days or doses? Yes = 1; no = 0
Did patient reduce or cut down the prescribed amount per dose? Yes = 1; no = 0
Did patient take any extra doses or more medication than prescribed? Yes = 1; no = 0
Did patient report ‘‘do not know’’ in response to any questions? Yes = 1; no = 0
Did patient refuse to answer any questions? Yes = 1; no = 0
Table 2 NCC MERP Classes
Class Content
A Circumstances or events that have the capacity to cause error
B An error occurred but the error did not reach the patient
C An error occurred that reached the patient but did not cause patient harm
D An error occurred that reached the patient and required monitoring to confirm
that it resulted in no harm to the patient and/or required intervention to preclude harm
E An error occurred that may have contributed to or resulted in temporary harm
to the patient and required intervention
F An error occurred that may have contributed to or resulted in temporary harm
to the patient and required initial or prolonged hospitalization
G An error occurred that may have contributed to or resulted in permanent harm
H An error occurred that required intervention necessary to sustain life
I An error occurred that may have contributed to or resulted in the patient’s death
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patients in the intervention group (see Fig. 1). Patient
characteristics are represented in Table 3. The character-
istics of both groups did not differ.
Sixty-eight percent of patients in the control group had
at least one discrepancy or prescription error against 39%
in the intervention group (RR 0.57 (95% CI 0.37–0.88)).
The percentage of medications with a discrepancy or pre-
scription error in the control group was 14.6% and in the
intervention group it was 6.1% (RR 0.42 (95% CI
0.27–0.66)) (see Table 4).
Prescription errors are most common in both groups.
These are followed by re-start of discontinued medication
and use of higher dose of medication in the control group.
In the intervention group prescription errors are followed
by discontinuation of prescribed medication and use of a
lower dose of medication (see Table 5).
In the intervention group as well as the control group the
highest percentage of the total number of prescription
errors and discrepancies fell into class B of the NCC
MERP-index (36% vs. 53%). The percentage of class E or
Control (n = 44) 
Excluded (n = 30) 
     Declined participation: 27 
     Died before randomization: 3 
Control (n = 48) 
Intervention (n = 41) 
Screened (n = 119) 
Not completed (n = 4) 
     Lost to follow up: 2 
     Died: 2 
Intervention (n = 41) 
Randomised (n = 89) 
Fig. 1 Study participant
flowchart
Table 3 Patient characteristics
a Tested with t test
b Tested with Pearson Chi-
square
Control
(n = 44)
Intervention
(n = 41)
P value
Age (years ± sd) 72 ± 10 74 ± 12 [0.05a
Sex (% male) 75 59 [0.05b
Time to follow-up (days ± sd (range)) 23 ± 10 (6–40) 24 ± 12 (7–48) [0.05a
Education (% primary school only) 39 42 [0.05b
Single or cohabitating (% single) 41 46 [0.05b
Chronic co-morbidity (CDS ± sd) 8 ± 3 8 ± 3 [0.05a
Treatment at the heart failure clinic
before admission (% no)
75 78 [0.05b
Length of admission (days ± sd) 12 ± 8 13 ± 7 [0.05a
Medication at moment discharge (number ± sd) 9 ± 3 10 ± 4 [0.05a
Living conditions after discharge
At home (%) 66 66 [0.05b
At home with additional care (%) 14 22
Residential home for elderly people (%) 20 12
Patient control over medication (% yes) 82 81 [0.05b
NYHA class at discharge
I/II (%) 52 56 [0.05b
III (%) 48 39
IV (%) 0 5
Pharm World Sci (2010) 32:759–766 763
123
higher was 32% in the intervention group and 29% in the
control group (see Table 6).
No difference was found in the estimate of adherence
between both groups: 79.5% in the control group had a
BMQ score C 1 (potentially non-adherent) versus 78.0%
in the intervention group (RR: 1.07 (95% CI 0.47–2.44)).
Discussion
This study has investigated the effect of a discharge service
by a clinical pharmacist on the occurrence of discrepancies
and prescription errors in a population of heart failure
patients. The percentage of patients with one or more
discrepancies or prescription errors has been lowered by
almost a half (68% vs. 39%).
International studies show that supervision of and pro-
viding heart failure patients with information at the time of
discharge as well as postdischarge support reduces the
number of readmissions and improves the patient’s quality
of life [21–23]. It was not possible in this study to measure
the number of readmissions caused by incorrect medicine
use because it was considered unethical to leave discrep-
ancies uncorrected during the check up at the outpatients’
clinic. However, by classifying discrepancies and pre-
scription errors into classes of seriousness an estimate can
Table 4 Discrepancy/
prescription error
Intervention Control Total
Number of patients with a discrepancy/
prescription error
16 30 46
Number of patients without a discrepancy/prescription error 25 14 39
Total 41 44 85
Relative risk (95% CI) 0.57 (0.37–0.88)
Number of medications with a discrepancy/
prescription error
25 62 87
Number of medications without a discrepancy/
prescription error
382 363 745
Total 407 425 832
Relative risk (95% CI) 0.42 (0.27–0.66)
Table 5 Classification and examples of discrepancies and prescription errors
Example Control,
no (%)
Intervention,
no (%)
Re-start of discontinued
medication
Before hospitalization a patient was prescribed verapamil. During
hospitalization this was stopped. After discharge he was still taking
verapamil because ‘‘nobody told me to stop’’C
9 (15) 2 (8)
Discontinuation of
prescribed medication
Not filling a prescription for a loop diuretic, because ‘‘I already use a diuretic
(hydrochlorothiazide)’’. Readmission within 2 weeksC
6 (10) 6 (24)
Use of higher dose
of medication
Discharge prescription and written information for patient: bumetanide 1 mg
tablet, once a day 2 mg
7 (11) 2 (8)
The pharmacy delivered tablets of 2 mg. The patient took 2 tablets of 2 mg
instead of oneC
Use of lower dose
of medication
Discharge prescription: paracetamol 1,000 mg four times a day. Patient used
500 mg four times a dayI
1 (2) 4 (16)
Use more frequent Discharge prescription: lactulose if necessary; the label of the pharmacy
prescribed twice a dayC
2 (3) –
Use less frequent Discharge prescription: lactulose once a day; the patient took it if necessaryI 6 (10) 2 (8)
Incorrect time of taking Discharge prescription: calcium at bedtime due to interaction with
ferrofumarate. Patient took both tablets at the same timeI
1 (2) 2 (8)
Prescription error—dosage
error
Discharge prescription: acenocoumarol 1 mg once a day. This should be:
according to schemeC, I
30 (48) 7 (28)
Prescription error—dosage
form error
Discharge prescription: thiamine injections. This should be tabletsC
Total 62 (100) 25 (100)
C Control; I intervention
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be made of the possible consequences. The percentage of
discrepancies and prescription errors in class E or higher
(error and harm) is similar in both groups but the absolute
numbers decrease by half in the intervention group.
The percentage of patients with at least one discrepancy
or prescription errors (68% vs. 39%) was consistent with
other general reports describing medication discrepancies
in 14.1–59.6% of patients at discharge [4, 24–26].
Although a variety of factors contribute to the occurrence
of medication discrepancies, prescribers often fail to rou-
tinely compare a patient’s inpatient medication list with his
or her preadmission list at the time of prescribing and may
not communicate medication information effectively at the
time of discharge.
The fact that the percentage of patients who are poten-
tially non-adherent is similar in both groups is not sur-
prising. It is a known fact that a combination of
interventions spread out over more than 3 weeks is needed
to improve medication adherence [7, 27].
This study is limited in several aspects. First, medication
discrepancies arising at the moment of admission were not
included in the study. Results of the study by Bolas et al.
[28] show that preparation of an accurate medication
record at admission by a community liaison pharmacist
reduces the number of these discrepancies. A combination
of admission and discharge consultations could have led to
a further decrease in the number of discrepancies.
Second, the interventions in this study were done by one
clinical pharmacist in one hospital only, which limits the
generalisability. Yet, the study is one of the few European
studies that provides information on a clinical pharmacist
discharge service outside the UK and the situation in this
single hospital is likely to be similar to many other European
hospitals with respect to the limited number of clinical phar-
macists. As the study focuses on a specific high risk group,
these limited resources may be used in an effective way when
implementing the intervention as described in this study.
Third, less patients were included in the study than the
calculated group size. Nonetheless, a statistically signifi-
cant effect of the intervention could be demonstrated. The
results need to be interpreted in the light that the prede-
termined sample size was not achieved.
Finally, the BMQ only provides an indication for
potential non-adherence. Therefore it is not possible to
distinguish between good or poor levels of adherence.
Strengths of the study are its randomized design and the
assessment of the discrepancies by a multidisciplinary
team. Other studies often solely rely on the assessment by
pharmacists and they may assess the clinical relevance of
discrepancies different than doctors [29].
Future studies should be performed investigating clini-
cal pharmacist discharge services in multicenter settings,
preferably using readmissions as a clinical endpoint. Such
studies should also pay attention to aspects as patient sat-
isfaction and quality of life.
Conclusion
Information about (side)effects and changes in the drug
therapy given by a clinical pharmacist combined with a
written overview of the discharge medication and com-
munication to both the community pharmacist and the GP
reduces discrepancies and prescription errors within a
population of heart failure patients. No effect on non-
adherence was found in this short follow-up study.
Table 6 Clinical relevance and examples of the discrepancies and prescription errors
NCC
MERP
index
Example Control, no
(%)
Intervention,
no (%)
A Discharge prescription: zopiclon at bedtime. On advise of the pharmacy this prescription stoppedI – 1 (4)
B Discharge prescription: acenocoumarol 1 mg once a day. This should be: according to schemeC, I 33 (53) 9 (36)
C Before hospitalization a patient was prescribed nitroglycerin patch. During hospitalization this
was stopped. After discharge she was still using nitroglycerinC
9 (15) 7 (28)
D Discharge prescription: amiodaron 200 mg three times a day. This should be reduced to 200 mg
once a day after a weekC
2 (3) –
E Before hospitalization, a patient was prescribed lisinopril/hydrochlorothiazide. During hospitalization
hydrochlorothiazide was stopped. After discharge the patient still used the combination tabletC, I
15 (24) 7 (28)
F Not filling a prescription for a loop diuretic, because ‘‘I already use a diuretic (hydrochlorothiazide)’’.
ReadmissionC
3 (5) 1 (4)
G – –
H – –
Total 62 (100) 25 (100)
C Control; I intervention
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